Valerian Root Extract

For the Treatment of Sleeping Disorders, Tenseness and Irritability
Introduction

EUROMED is a company specialized in making botanical extracts and active principles used as phytomedicines in pharmacy. EUROMED develops and produces these from therapeutically active raw materials.

The botanical raw materials are subject to strict selection and inspection, and products are manufactured according to methods developed by the EUROMED company. They include inspections to guarantee a standard quality from both analyticochemical and therapeutical points of view and take into consideration the state of art in different fields: research and development, analyses, processes and devices, therapeutic applications on a scientific basis.

EUROMED guarantees the quality of its products by a broad phytochemical know-how.
Table of Contents

1  Valeriana officinalis L. Extract: General Information  4
   1.1 Description  4
   1.2 Indications  4
   1.3 Extract Specifications  5
   1.4 Dosage and Methods of Administration  5
   1.5 Contraindications and Interactions  5
   1.6 Side-effects  6

2  From Plant to Extract  7
   2.1 Valerian Root (Valerianae radix) Botanical Data and Nomenclature  7
   2.2 Historic Use  8
   2.3 Chemistry of Valeriana officinalis L. Root  9
   2.4 Preparation of the Extract and Quality Control  12
   2.5 Standardization  14

3  Sleeping Disorders  15

4  Pharmacology  20
   4.1 Reduction of local cerebral glucose metabolism in the cortex and limbic system, reduction of motility  20
   4.2 Affinity to GABA-A receptor and release of [3H]-GABA  21
   4.3 Relaxation of smooth muscles  22

5  Toxicology  23

6  Clinical Pharmacology  24

7  Proof of Clinical Efficacy  27
   7.1 Clinical Trials with Placebos  27
   7.2 Clinical Trials with Combination Preparations versus Placebo  30
   7.3 Drug Monitoring Studies  32
   7.4 Anti-Stress Activities  33
   7.5 Therapeutic Safety  33

8  Summary  34

9  Bibliography  36
1 **Valeriana officinalis L. Extract:**

**General Information**

1.1 **Description**

Extract of valerian (as available from EUROMED) is a standardized hydroalcoholic herbal extract of the root of *Valeriana officinalis L.* (Fam. Valerianacae).

*Valeriana officinalis* root extract is a safe and effective herbal medicinal product for the treatment of nervous tension and especially difficulties in falling asleep or lack of sleep quality.

After a few days of treatment, relief from the above-mentioned symptoms is seen in most patients.

*Valeriana officinalis* has proved to be sleep promoting and sleep quality enhancing. Valerian extract does not interact with other drugs, food or alcohol [2, 9, 13].

Unlike other medications with benzodiazepines, no dependency, adaption, “hang-over-effect” the next morning or other serious side-effects have been reported for the extract of *Valeriana officinalis* at the recommended dosages.

1.2 **Indications**

*Valeriana officinalis* root extract is acknowledged and recommended as treatment for difficulties in falling asleep, tenseness, restlessness and irritability [9, 10, 13].

*Valeriana officinalis* has been approved as safe (GRAS = generally recognized as safe) for food use in the United States [17, 32].
1.3 Extract Specifications

Valerian root extract consists of the subterranean organs of *Valeriana officinalis* L., including the rhizome, roots and stolons, carefully dried at a temperature below 40°C.

It contains not less than 0.5 % *V/m* of essential oil. The material complies with the European Pharmacopoeia [13, 14].

Valerian root preparations usually contain about 45 mg to 450 mg of *Valeriana officinalis* extract (as available from EUROMED).

1.4 Dosage and Methods of Administration

A daily oral dose of 500 mg up to 3000 mg is common practice, for tenseness, restlessness and irritability up to 3 times daily; as a sleeping-aid 1 single dose \( \frac{1}{2} \) to 1 hour before bedtime, with an earlier dose during the evening, if necessary [12, 13, 41, 42, 43].

Table 1 gives a survey of popular European *Valeriana officinalis* monopreparations available on the market.

1.5 Contraindications and Interactions

There are no known contraindications to the longterm use of Valeriana officinalis extract [9].

For pediatrics (children from age one) and geriatrics, non-alcoholic valerian preparations are accepted in Europe as suitable [2, 13].

No interactions with drugs usually prescribed have been reported.
1.6 Side-effects

*Well tolerated, non-addictive*

No adverse effects have been confirmed. Valerian root is very well tolerated and non-addictive.

Table 1: European Monopreparations containing *Valeriana officinalis* root extracts

<table>
<thead>
<tr>
<th>Preparation Name</th>
<th>Method of Extraction</th>
<th>Content of Extract / mg</th>
<th>Total Extract [mg/day] for diurnal sedation</th>
<th>Total Extract [mg/day] for Sleep-Induction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baldrian-Dispert/ stark am Tag</td>
<td>Ethanolic, ethanolic</td>
<td>45 / 125</td>
<td>45 - 135 several times / 250 - 500 several times</td>
<td>135 - 270 / 200 - 400</td>
</tr>
<tr>
<td>Baldrianetten</td>
<td>no data</td>
<td>200</td>
<td>200 - 600 up to 5 times</td>
<td>200 - 400 / 1/2 h before sleep</td>
</tr>
<tr>
<td>Baldrian Phyton</td>
<td>no data</td>
<td>200</td>
<td>400 - 1800</td>
<td>400 - 1800 / 1/2 h before sleep</td>
</tr>
<tr>
<td>Baldrisedon mono</td>
<td>methanolic</td>
<td>190</td>
<td>380 - 570 several times</td>
<td>380 - 570 / 1/2 h before sleep</td>
</tr>
<tr>
<td>Benedorm Baldrian</td>
<td>ethanolic</td>
<td>442</td>
<td>441 - 1324</td>
<td>441 - 882 / 1 h before sleep</td>
</tr>
<tr>
<td>Kneipp Baldrian Tableten (tablets)</td>
<td>no data</td>
<td>500</td>
<td>2000 - 6000</td>
<td>2000 - 3000 / 1/2 to 2 h before sleep</td>
</tr>
<tr>
<td>Regivital Baldrian Perlen</td>
<td>ethanolic</td>
<td>86</td>
<td>257 - 770</td>
<td>257 / 2 h before sleep</td>
</tr>
<tr>
<td>Sedalint Baldrian</td>
<td>no data</td>
<td>220 up to three times</td>
<td>440 - 660 up to three times</td>
<td>440 - 660 / up to three times</td>
</tr>
<tr>
<td>Sedonium</td>
<td>ethanolic</td>
<td>300</td>
<td>600 several times</td>
<td>600 before bedtime</td>
</tr>
<tr>
<td>Valdispert/</td>
<td>ethanolic</td>
<td>45</td>
<td>45 - 135 several times</td>
<td>135 - 280</td>
</tr>
<tr>
<td>Valdispert 125</td>
<td>ethanolic</td>
<td>125</td>
<td>250 - 500 several times</td>
<td></td>
</tr>
</tbody>
</table>
2 From Plant to Extract

2.1 Valerian Root (*Valerianae radix*)

Botanical Data and Nomenclature

*Valerian root*

The genus *Valeriana* is found throughout the world and consists of more than 230 species. Only *Valeriana wallichii* D.C. (temperate zones of the Himalaya), *Valeriana edulis* Nutt.ssp. *procera* F.G. Meyer (Mexico) and especially *Valeriana officinalis* L. with a broad documented clinical efficacy are of importance to phytotherapy.

*Valeriana officinalis* L. is a perennial herbaceous plant widely distributed mostly in Europe but also in some parts of South America and Asia. It is nowadays cultivated on a large scale for medicinal use in Europe. The plant thrives on the damp surfaces of ditches and ponds, marshlands and at the edges of forests in temperate zones up to 2400 m.

*Valeriana officinalis* is distinguished by its short, sometimes stoloniferous rhizomes and grooved stalk, growing to a maximum height of approximately 6 feet.

The rhizomes and roots, with and without stolons, are the basic material used for phytopharmaceutical products. Harvesting period is autumn or spring. The roots are carefully washed with water to remove soil and dried at a temperature below 40°C immediately after harvesting to prevent degradation of the active principles.
The smell of fresh roots is at first pleasant with a sweet musky note but soon turning into the typical, for most people rather appaling “valerian“ odor.

The name valerian or Valeriana first appeared in literature between the 9th and 10th century, its true origin is unknown. Most authors claim that Valeriana derives from the Latin words “valere“ (to be in health) or “valeo“ (to be strong), probaly in reference to the plants powerful healing properties or strong odor. Others suspect that the plant was named after the Roman province Valeria at the river Danube or was given in honour of the Roman emperor PUBLIUS AURELIUS LICINUS VALERIANUS. Other ancient names for valerian are “phu” (or “fū”) and “nard” [7, 17, 26, 32, 49].

Figure 1: Valerian root

2.2 Historic Use
The history of Valeriana goes back more than 2000 years (Hippocrates 460-370 B.C.).

The drug has been used not only in European medicine but also in Traditional Chinese Medicine (TCM) and Indian Ayurvedic for centuries. Galen (131-201 A.D.) first prescribed the drug as a treatment for insomnia.

The use of valerian as a sedative or nervine in modern medicine was initiated by JOHN HILL, a British physician, in the 18th century and soon Valeriana officinalis developed into a very popular drug prescribed to cure various kinds of symptoms related to nervous conditions like insomnia, restlessness, gastrointestinal disorders, hysteria, anxiety and many more.

Valerian was listed as official medication both in England and the United States until the late 1940’s (London Pharmacopoeia 1618-1948, United States Pharmacopoeia 1820-1936, National Formulary 1888-1946).

Today it continues to be an official medicinal plant in the pharmacopoeias of many European countries. Valerian is acknowledged and recommended as a mild diurnal sedative in cases of irritability and restlessness and it is known as a safe and efficient sleep-inducing drug due to its antispasmodic effects on smooth muscles and depressant properties in the central nervous system [8, 17, 33, 34, 32, 60].

2.3 Chemistry of Valeriana officinalis L. Root
Valeriana officinalis root consists of several groups of substances. They are identified and quantified according to modern scientific analytical methods [23, 27].

Table 2: Contents of Valeriana officinalis L. Root

<table>
<thead>
<tr>
<th>Compounds identified in Valerian root</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Volatile oil 0.3 to 0.8 %, depending on condition of soil and time of harvest [26], 0.1 to 2 % from cultivated plants [49]. So far the following constituents have been isolated: various derivatives of kessane, monoterpenes and sesquiterpenes (Figure 2) [63, 64].</td>
</tr>
<tr>
<td>• Iridoids also known as valepotriates and their degradation products baldrinal, homobaldrinal and viltroxal [26].</td>
</tr>
<tr>
<td>• Small amounts of alkaloids as well as amino-acids (GABA, thyrosine, glutamine), flavonoids, triterpenes, various minerals and sugars [26].</td>
</tr>
</tbody>
</table>

Leading substances for identification and standardization are the cyclopentane-sesquiterpenes valerenic acid acetoxyvalerenic acid, hydroxyvalerenic acid and valerenal (Figure 2), as those components are only found in Valeriana officinalis L. [27].
The active principles of the drug are so far not known, as various tests and trials with isolated constituents did not fully explain the biological activities of *Valeriana officinalis*. Research was mostly concentrated on the sesquiterpenes and valepotriates.

Most authors conclude, that not one single constituent is responsible for the sedative and relaxing properties of *Valeriana officinalis*, but that several components must act synergistically, or that even other unknown substances, so far not isolated, may contribute to the active principle [24, 34, 47, 48, 49].
2.4 Preparation of the Extract and Quality Control

The plant material used for *Valeriana officinalis* root extract manufactured by EUROMED originates primarily from cultivations. The growing and processing specifications are established in order to standardize conditions of cultivation, harvest and most importantly drying and storage. Thus the excellent quality of the EUROMED product is guaranteed.

Various substance groups have been isolated in valerian extracts. The best evaluated active components are valerenic acid and valepotriates. As clinical trials showed biological activities of extracts in which valepotriates were absent and the cyclopentane-sesquiterpenes valerenic acid, acetoxyvalerenic acid and valerenal are found only in the species *Valeriana officinalis* L., EUROMED established the valerenic acids as leading substances for identification and standardisation. The level of those components is measured experimentally in order to optimize the production process and assure a consistent high quality of the *Valeriana officinalis* extract [26].

When the plant material arrives at EUROMED, an exhaustive control of the raw material is carried out according to worldwide established methods, paying special attention to the content of valerenic acids to assure a continuous excellent quality of the final product.
Furthermore, **EUROMED** evaluates possible contaminations of the drug. In doing so, the company assures that the limits fixed by international norms or literature are not surpassed.

**EUROMED** applies an extraction process which provides a high yield of valuable constituents and a high-grade extract in a careful way. According to the original processes **EUROMED** produces a dry extract from *Valerianae radix*:

- **Extr. Valerianae Off. E Rad. Siccum**  
  (Valerian Dry Extract)  
  Cont. 0.8 % Valerenic Acids.
Valerian root extract satisfies the highest quality standards. This way it is possible to meet the requirements for an effective and safe medication.

### 2.5 Standardization

The consistent batch to batch quality of the Valerianae radix extract is guaranteed by the standardized production process. The analytical specifications of the Valerian root extract are:

### Analytical Specifications

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fine powder</td>
<td>Brown color, characteristic odor and savor</td>
</tr>
<tr>
<td>Identification</td>
<td>HPLC Fingerprint</td>
</tr>
<tr>
<td>Solubility</td>
<td>Soluble in hydroalcoholic solutions</td>
</tr>
<tr>
<td>Loss on drying</td>
<td>Max. 5.0 %</td>
</tr>
<tr>
<td>Ash</td>
<td>Max. 10.0 %</td>
</tr>
<tr>
<td>Assay</td>
<td>Valerenic acids min. 0.8 % (HPLC Method)</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Acc. Ph. Eur. 3rd ed., 5.1.4., category 3B</td>
</tr>
</tbody>
</table>
Due to euromed's standardized production process a consistent quality is guaranteed which meets the highest standards and requirements for effectiveness and safe use of the medication.

3 Sleeping Disorders

Normal sleep is characterized by a defined cycle of different sleep stages (Figure 4), repeated several times during the night with direct correlation to EEG\(^1\)-frequency patterns (alpha-waves: 8 – 13/sec, theta: 4 – 7/sec, delta: 0.5 – 3/sec, beta: 14 – 30/sec)\(^2\), nocturnal body movements, frequencies of breathing and heartbeat as well as body temperature. Sleep onset starts with stage 1, leading gradually over stage 2 to stages 3 and 4 (deep sleep phase), followed by stage 5 or REM\(^2\)-phase. Stage 2, a sufficient amount of stages 3 and 4 during the first sleep cycles and especially stage REM seem to be the most important parameters for the judgement of sleep quality. Significant reduction or absence of REM-phases may even lead to severe psychotropic symptoms. Patients with sleep disorders show a prolonged period of time before onset of sleep stage one and/or various changes in normal sleep patterns [3, 21, 45].

---

\(^1\) EEG: Electro-encephalo-gram

---
Figure 4: Normal sleep pattern of healthy young adults

About one third of the population worldwide complains of sleeping problems (Table 3). Roughly one third is related to underlying diseases, one third to psychiatric problems and one third to non-organic psychophysiological insomnia. According to definition in literature, symptoms of chronic insomnia are prevalent several times a week for a period of more than a month. The reasons are manifold (Table 4).

Table 3: Sleeping problems

- Difficulty in falling asleep
- Difficulties to sleep through
- Early awakening
- Irritability, restlessness and fatigue during daytime

Table 4: Reasons for sleeping disorders

---

2 REM: Rapid Eye Movement
- Environmental reasons like shift-working, traffic-noise
- Somatic problems like nervousness, tension, restlessness
- Disorders of circadian rhythm with asynchrony relative to typical environmental patterns
- Psychiatric disorders
- Old age
- Cerebral and other severe diseases
- Pharmacological interferences like alcohol, caffeine, nicotine, medication

Benzodiazepines and barbiturates are often prescribed medications, but sleep architecture is extremely altered and side-effects are severe (Table 5).

Table 5: Problems in Treatment with Synthetic Sedatives
- Sleep architecture (EEG-patterns, especially sleep-stage 3 and 4 and REM-phase) are influenced in a negative way
- Abuse (suicide attempts)
- Dependency
- Hang-over-effect next morning
- Concentration deficits during daytime
- Danger when driving or operating machines
- Synergistic action with alcohol
- Apathy or disorientation in geriatric patients
- Increase of sleep apnea
- Withdrawal symptoms, when discontinuing therapy

Over the years, the requirement to find a medication that is safe, without adverse effects and not interacting with other drugs or alcohol became mandatory.

As valerian is known for centuries to fulfill these requirements, research concentrated on this drug and its combination-preparations during the last 30 years especially in Germany, France and Switzerland.
According to the results of various tests and trials it can be stated, that extract of *Valeriana officinalis* is a safe and efficient drug to induce sleep, enhance sleep quality and leave the patient rested, refreshed and fully concentrated the next morning. Sleep patterns are normalized, the drug may even be useful to reduce withdrawal symptoms when weaning patients off barbiturates.

Compliance is usually good, patients responses are excellent [1, 3, 4, 8, 33, 32, 36, 37, 45, 47, 50, 54, 59, 61, 66].
4 Pharmacology

The sedative and sleep-inducing effect of Valeriana officinalis is not based on an isolated constituent or mechanism, as it is the case with many herbal remedies [24, 48].

So far a presumably synergistical action of several active components or even interaction of presently not yet isolated components is assumed for the biological activity of the whole extract [24, 34, 47, 48, 49].

4.1 Reduction of local cerebral glucose metabolism in the cortex and limbic system, reduction of motility

By means of desoxy-glucose-technique (SOKOLOFF) possible central nervous system effects of valerian extract on rat brains were evaluated. After intraperitoneal injection of 50 mg/kg bodyweight a marked reduction of local cerebral glucose metabolism especially in the cortex and limbic system could be seen [24].

In another study effects on spontaneous motility, thiopental sleeping-time and pentetrazol-induced toxicity were tested on female mice by administering a commercially available valerian root extract. Pronounced sedative properties were revealed with respect to a reduction in motility and an increase in the thiopental sleeping-time. A direct comparison with diazepam and chlorpromazine showed a moderate sedative activity for the tested extract [44].
4.2 Affinity to GABA-A receptor and release of [³H]-GABA

Hydroalcoholic and aqueous total extracts of valerian root showed affinity to the GABA³-A receptor in rat brains. The chemical nature of this activity was not connected with sesquiterpenes or valepotriates. Interaction of unknown constituents could represent the molecular base for the sedative effect observed both in man and experimental animals.

Interaction with GABA receptor is possible

For the hydroalcoholic extracts, a contribution to the sedative effect cannot be excluded due to the interaction of their valepotriate constituents with the allosteric sites of GABA receptors controlling chloride anions influx [48].

An aqueous extract of valerian (100 g of the extract containing 55 mg of valerenic acids) inhibits the uptake and induces the Ca²⁺-dependent release of [³H]-GABA previously accumulated in synaptosomes isolated from rat brain cortices. This inhibition of uptake and/or stimulation of GABA release from nerve terminals may increase the extracellular concentration of this neurotransmitter in the synaptic cleft at levels sufficiently high to activate GABA receptors [57].

The above mentioned extract contains several amino acids with a relatively high concentration of GABA (about 5 mM) which proved sufficient to induce the release of [³H]-GABA accumulated in synaptosomes by a homoexchange mechanism.

³ GABA: Gamma-aminobutyric acid
The mechanism of action in vivo is still unclear, as GABA is supposed not to penetrate the blood-brain barrier readily. However there is evidence, that GABA effects are not restricted to synaptic transmissions alone but that it is also present and may even be a neurotransmitter in a variety of cell types inside and outside the nervous system.

Also high concentrations of glutamine (about 14 mM) were found, which could explain sedative effects of valerian extracts in vivo, as glutamine can cross the blood-brain barrier and possibly is taken up by nerve terminals and subsequently metabolized to GABA in GABA-ergic neurons. Moreover addition of exogenous glutamine stimulates GABA syntheses in synaptosomes and brain slices [58].

4.3 Relaxation of smooth muscles

Isovaltrate, valtrate and the essential oil compound valeranone caused a suppression of rhythmic contractions in a closed part of the guinea-pig ileum in vivo. The same compounds and dihydrovaltrate relaxed potassium stimulated contractures and inhibited BaCl₂ contractions in guinea-pig ileum preparations in vitro. It can be concluded, that valerian root compounds relax stimulated smooth muscle cells probably by acting as muscolotropic agents [30].
VALERIAN ROOT

5 Toxicology

Very low toxicity

A low order of toxicity was reported for an ethanolic extract of valerian root. The LD$_{50}$ by intraperitoneal injection into mice was found to be 3.3 g/kg body weight. When this extract was administered intraperitoneally to rats daily for 45 days in doses ranging from 400 – 600 mg/kg bodyweight no significant changes in weight, blood or urine were observed in comparison with control animals [13].

An alcoholic extract of valerian root was administered to rats at dosages of 300 mg/kg and 600 mg/kg body weight per day for 30 days. Compared to control animals, no significant differences were found in growth, arterial pressure, weight of key organs or hematological and biochemical parameters [15].

In acute oral toxicity tests the LD$_{50}$ of valeranone was greater than 3 g/kg body weight in both rats and mice [56].
6 Clinical Pharmacology

A normalization of sleep-architecture, reduction of sleep-latency and wake periods and improvement of sleep quality is seen in EEG-studies and polysomnography after application of valerian root extracts.

Geriatric patients, most of whom had been taking benzodiazepines, were substituted with a combination-preparation of hop flowers and valerian. The herbal remedy normalized sleep architecture [16].

24 female subjects received either 10 mg diazepam or placebo or a valerian extract preparation (1200 mg dry extract). The resting EEG showed a marked increase in relative power in the delta, theta and slow alpha frequency ranges 120 min after ingestion of valerian extract. In contrast to diazepam, there was no increase in the power of the beta frequency range. The subjectively experienced tiredness increased markedly both after valerian and diazepam 120 min after ingestion [61].

The influence of a proprietary preparation containing 405 mg of an aqueous-alcoholic dry extract of valerian was investigated on female subjects. Valerian reduced sleep induction time and improved sleep quality. These subjective findings were confirmed by EEG: long-wave sleep (sleep-stadium 3 and 4) was increased and sleep-stadium 1 was decreased. No influence was observed on the REM sleep as well as on the frequency of waking during night time [62].
After single administration of 1200 mg valerian extract a significant increase in the power in the delta and theta frequency bands was seen in an EEG study with 16 healthy volunteers, giving an indication of a specific sedative effect. After repeated administration (600 mg daily) over a course of 14 days, the quantified EEG showed a rise in the theta, alpha-1 and beta-1 frequency ranges. These EEG changes provide objective evidence of a psychosedative effect of valerian [11].

Effects of 60 and 120 mg of a valerian preparation were investigated by computer analysis of sleep stages and psychometric methods. After application of 120 mg valerian, the frequency of REM-phases declined during the first half of the night, whereas during the second part a surplus appeared. Changes in the beta-intensity of the EEG during REM-sleep showed a stronger hypnotic effect for the 120 mg dosage. Maximum effect was observed between 2 and 3 hours post medication [21].

15 patients with psychophysical insomnia were investigated by polysomnography for 4 weeks, taking a combination preparation containing 500 mg valerian and 120 mg hops on 28 consecutive nights, in a double-blind, placebo-controlled, randomized, parallel group design. Verum medication significantly decreased slow-wave-sleep percentages, but increased sleep stage 2. These effects correspond to effects caused by benzodiazepine receptor antagonists and seem to be a feature of the GABA-ergic effects of valerian preparations [55].
A normalization of sleep architecture was seen in patients with chronic sleep disorders after taking a commercially available combination preparation of 500 mg valerian and 120 mg hop for two weeks (Figure 5) [18].

Figure 5: Restructured hypnogramm after therapy with 500 mg valerian and 120 mg hop (b) in comparison to hypnogramm before therapy (a) [18]
7 Proof of Clinical Efficacy

7.1 Clinical Trials with Placebos

In the 1980s, Leathwood, Chauffard et al. published a number of studies on the effect of valerian extract on sleep patterns. Sleep quality was subjectively measured by the patient and to some extent confirmed by EEG. A significant decrease in subjectively evaluated sleep latency and also a significant increase in sleep quality was reported especially among geriatric patients and subjects who considered themselves poor and irregular sleepers (Figure 6). Dream recall and nocturnal movement were apparently not affected, no drowsiness was reported the next morning. The authors concluded, that valerian is at least as effective as small doses of barbiturates or benzodiazepines [41, 42, 43].

![Graph showing response frequency of sleep quality]

Figure 6: Percentage of habitually poor or irregular sleepers reporting a mean rating over 3 nights of better or worse sleep than usual following placebo or valerian treatment [41, 42, 43].
The sleep-inducing effect of valerian extract was studied in two groups of healthy volunteers, one (n = 10) sleeping at home, the other (n = 8) in the sleep laboratory. Evaluation was conducted on the basis of self-rating scales, questionnaires and night-time motor activity. In the home sleeping group, doses of 450 mg and 900 mg of the valerian extract had a significant, dose-dependent, sleep-promoting effect. Perceived sleep latency and wake time after sleep onset were reduced. Night-time motor activity was enhanced in the middle third of the night and reduced in the last third. Objective and subjective findings in the laboratory group corresponded to those observed under home conditions [6].

78 elderly patients received 270 mg valerian extract in coated tablets or a placebo. The study showed significant improvements in sleep latency time and sleep quality in the valerian treated group according to psychometric scales and subjective ratings [35].

A placebo-controlled double-blind study was carried out on 121 patients suffering from non-organic insomnia according to ICD-10 (F 51.0) over the course of 28 days [66]. 600 mg of an ethanol-water valerian root extract were taken one hour before retiring to bed. In the valerian treated group (n = 61) the Clinical Global Impression (CGI) improved significantly after 2 weeks (p < 0.05) and was highly significant after 4 weeks (p < 0.001). The change in state was given as “very much improved“ or “improved“ in 55.9 % of the cases, whereas these statements were made for placebo only in 25.9 % of the cases.
The self-rating scale according to VON ZERSSEN was used to obtain an objective and quantifiable evaluation of the changes in well-being. After 4 weeks, the insomnia in the valerian treated group was considerably improved in comparison to the placebo treated group (p = 0.002). Another self-assessment scale used was GÖRTELMEYER’S sleep questionnaire. A significant difference between placebo and valerian treated group was found for the factor “sleep quality“ in favour for the valerian extract (p = 0.035). In the valerian treated group the mean of the factor “refreshment after sleep“ was close to the one given for healthy persons. The efficacy of the extract was rated as very good to good in 66 % of the cases by patients and in 61 % by physicians [66].

![Figure 7](chart.png)

Figure 7: Decrease in the self-rating scale according to VON ZERSSEN during a treatment period of 28 days with placebo or valerian. In the valerian treated group the score nearly improved to normal values.
In a double-blind cross-over study the long term effect of a valerian preparation was tested with 21 volunteers for 9 days. The subjects repeatedly had to fill in the sleep questionnaires SF-A and SF-B according to GÖRTELMEYER as well as the questionnaires VIS-A and VIS-M according to OTT, OSWALD, FICHTE and SASTRE. The statistical analysis showed significant improvement of quality in sleep, recuperation value and sleeping disposition as well as a significant decrease of frequency of waking-up, sleep latency, period of sleep disturbances and bad dreams. Side effects were not reported [22].

![Figure 8: Improvement of sleep quality according to VIS-M during the treatment (median ± SEM): 0 = very bad night, 100 = very good night [22].](image)

### 7.2 Clinical Trials with Combination Preparations versus Placebo
In a double-blind, placebo-controlled study, 4 coated tablets of a compound preparation (60 mg dried valerian extract and 100 mg extract of *humuli lupuli*) were given to 12 subjects complaining of sleep disorders during the second or third of three consecutive nights disturbed by heavy traffic noise (altogether 6 nights in the sleeping laboratory). On the other nights, 4 tablets containing placebo were administered. EEG, EOG\(^4\) and EMG\(^5\) data showed that prior drug administration reduced the noise induced disturbance of sleep stage patterns: slow-wave sleep (stage 3 and 4) and stage REM increased, sleep stage 1 and stage awake decreased [50].

A total of 575 patients (suffering from nervous sleep disorders) from 158 general practitioners were treated with a commercially available combination preparation containing valerian and hops or a placebo for seven days each. The biometric results in 491 patients were evaluated. The verum-medication was rated as more effective as the placebo by both, physicians and patients. 71 % responded to the medication and 89.2 % regarded tolerability of the drug as good or excellent [39].

\(^4\) EOG: Electro-oculogram  
\(^5\) EMG: Electro-myogram
Another study was carried out on a valerian preparation combined with hops and balm leaves. Subjects were 27 volunteers with self-reported sleep difficulties. A significant improvement in subjective sleep quality was seen with 44% reporting perfect sleep and 89% reporting improved sleep with verum-medication. No side effects were seen [46].

7.3 Drug Monitoring Studies

In an open multicentric study 11,168 patients were treated for ten days with a commercially available extract of valerian root. 72% of the patients with difficulties in falling asleep rated the therapy as successful, as well as 76% of the patients with discontinuous sleep and 72% with restlessness and tension [60].

60 patients treated with a non-alcoholic syrup containing valerian root extract showed proof of efficacy in 80%. Sleep latency and awakenings during the night were reduced by 50% [53].

A multicentric drug monitoring trial performed with 3,447 patients taking a valerian-hops preparation showed the following results: The number of patients who slept through without awakenings increased 5-fold, the number of patients feeling rested the next morning doubled. Tolerance was judged “very good“ or “good“ in 79.5% of the cases [29, 40].
7.4 Anti-Stress Activities

48 volunteers were placed under experimental “social stress“ conditions. In this double-blind study valerian root extract at a low dosage (100 mg) showed no apparent sedative effect but reduced subjective feelings of somatic arousal [38].

225 patients suffering from difficulties in falling asleep, sleeping through the night and/or states of nervous unrest were evaluated in an open, multicenter study. After a 2-week medication of a combination preparation (95 mg valerian root, 15 mg hop grains, 85 mg balm leaves) 82 % reported a significant improvement concerning the state of nervous unrest. External stressors were experienced as being less distressing, intercurrent somatic symptoms like headaches, dizziness, cardiovascular or gastrointestinal discomfort were also reported to be improved [52].

7.5 Therapeutic Safety

*Very well tolerated*

In general, valerian is very well tolerated. Side effects are rare in clinical trials as well as drug monitoring studies. No adverse effects have been confirmed [5, 9, 12, 13, 19, 20, 28, 31, 36, 51, 65, 66, 67].
Isolated valepotriates may cause gastric complaints as well as allergic reactions, yet, due to their unstable epoxide structure, they are absent from the extract as available from EUROMED [12].

8 Summary

Valerian has been used for more than 1000 years and is one of the most popular sleep aids at least in Europe. Over the past 30 years, more than 200 studies on the active ingredients and their pharmaco-biological effects have been published in scientific literature. Experimental data indicate a rational scientific basis for mild sedative qualities. Efficacy and safety of valerian root extract (as available from EUROMED) have been proved by a large number of trials. The European market is characterized by combination products, not monopreparations - therefore most of the clinical and pharmacological tests were conducted with valerian root extract in combination with e.g. hops. Commercially available products usually contain alcoholic extracts. Clinical trials also showed, that valerian, unlike chemical sleep medication, does not cause changes in natural sleep patterns, it normalizes sleep-architecture. The drug is very well tolerated and non-addictive. No toxic effects have been observed even after high dosage or overdose. After repeated administration no cummulative effects have been reported [32, 67].
Valerian Root

**No interactions**

There is no interaction with food, drugs or alcohol [2, 9, 13]. Valerian root extract was mostly tested in daily doses of 400 mg (range 45 - 1200 mg) on several hundred subjects.

Valerian improves sleep quality and reduces latency in falling asleep and can be considered a viable alternative to synthetic sedatives, moreover as there are no side-effects like hang-over or concentration problems etc. valerian extract even is used as supporting medication to ease withdrawal from benzodiazepines [54].

**No side effects**

**Mild sedative**

Valerian is also a mild diurnal sedative, it is not habit-forming and a proven safe natural ingredient.
9 Bibliography

[1] Ackermann
Baldrian – Therapiealternative ohne Suchtpotential
TW Neurologie Special, Sonderheft Januar 1996

[2] Ad hoc working group on herbal medicinal products of the EMEA
Proposal for a core-SPC for Valeriana radix
November 24, 1997

Schlafstörungen: Neue Erkenntnisse und deren klinische Anwendungen
Therapiewoche 41, 46 (1991) 3024-3027

The International Classification of Sleep Disorders

Aktuelle Daten, Kosten, Trends und Kommentare
Herausgegeben von Ulrich Schwabe
Gustav Fischer Verlag, Stuttgart, Jena, Lübeck, Ulm 315-317

Effect of Valerian on human sleep
Psychopharmacology 87 (1985) 406-9

Valeriaan en Valeriaan-preparaten
Pharm. Weekbl. 1994; 129 (2): 37-43

[8] Brown DJ
Herbal Prescriptions for Better Health: Valerian

Monograph: Valerianae radix (Baldrianwurzel)
Federal Legal Gazette (Bundesanzeiger) No 90, 15.05.1985, Corrected in
Federal Gazette No 50, 13.03.1990

[10] DAB (German Pharmacopoeia) 1997
Baldrianwurzeltrockenextrakt – Valerianae extractum siccum


[21] Geßner B, Klasser M
Untersuchungen der Wirkungen von Harmonicum Much auf den Schlaf mit Hilfe polygraphischer EEG-Aufzeichnungen

[22] Geßner B, Klasser M, Völ P
Untersuchung über die Langzeitwirkung von Harmonicum Much auf den Schlaf von schlafgestörten Personen
Therapiewoche 33 (1983) 5547-58

[23] Gobbato S, Lolla E
A new HPLC method for the analysis of valerenic acids in Valeriana officinalis extracts
Fitoterapia, Vol. 67, No 2, 1996, p. 159-162

Baldrianwirkungen im Gehirn der Ratte

[25] Hallen O
Klinische Neurologie

Hagers Handbuch der Pharmazeutischen Praxis: Drogen P-Z: Valeriana

[27] Hänsel R, Schulz J
Valeriansäure und Valerenal als Leitstoffe des offiziellen Baldrians.
Bestimmung mittels HPLC-Technik

[28] Hasler A
Keine Beeinträchtigung der Konzentrationsfähigkeit im Straßenverkehr durch Baldrian-Hopfen-Extract
unpublished report of Zeller AG

[29] Hasler A
Schlaf-Dragees von Zeller. Innovative Wirksamkeitsbeweise, revolutionär für ein Phytopharmakon
unpublished report, Zeller-AG

Antispasmodic Effects of Valeriana Compounds: An in-Vivo and in-Vitro Study on the Guinea-Pig Ileum
[31] Herberg KW
Doppelblinde Crossoverstudie zum Einfluß einer Hopfen-Baldrian-Kombination (Ivel®) Und von Placebo allein und in Kombination mit Alkohol auf Verkehrssicherheit und allgemeine Leistungsfähigkeit von Probanden (Study No. MI 9218)
TÜV Rheinland, Köln, April 1994, quoted in (12)

[32] Hobbs C
Valerian: The Relaxing and Sleep Herb
Botanica Press, Capitola, CA 1995

[33] Hölzl J
Baldrian: Ein Mittel gegen Schlafstörungen und Nervosität
DAZ 136. Jahrgang, Nr 10 7.3.96 751(17)-759(25)

[34] Hölzl J
Baldrianwurzel
Z. Phytotherapie 19 (1998) 47-54

Moderne Baldriantherapie gegen nervöse Störungen im Senium

Einfluß einer Hopfen-Baldrian-Kombination auf Leistungsfähigkeit und Verkehrssicherheit
Der Bayerische Internist 16 (1996) 32-6

[37] Kammerer E, Wegener T
Schlafstörungen und deren Behandlung. Stellenwert hochdosierter pflanzlicher Kombinationen
Naturremed 10 (1995) 14-26

[38] Kohnen R, Oswald W-D
The Effects of Valerian, Propanolol and their Combination on Activation, Performance and Mood on Healthy Volunteers under Social Stress Conditions
Pharmacopsychiat. 21 (1988) 227-8

[39] König Cd
Valverde Schlafdragées. Multizentrische Crossover- Prüfung gegen Placebo
Der informierte Arzt/Gazette Médicinale 18 (1991) 1835-9

[40] Lataster MJ, Brattström A
Die Behandlung von Patienten mit Schlafstörungen
[41] Leathwood PD, Chauffard F
Quantifying the effects of mild sedatives

[42] Leathwood PD, Chauffard F
Aqueous Extract of Valerian Reduces Latency to Fall Asleep in Man
Planta Medica 51 (1985) 144-8

[43] Leathwood PD, Chauffard F, Heck E, Munoz-Box R
Aqueous Extract of Valerian Root (Valeriana officinalis L.) Improves Sleep
Quality in Man

[44] Leuschner J, Müller J, Rudmann M
Characterisation of the Central Nervous Depressant Activity of a
Commercially Available Valerian Root Extract
Arzneim.-Forsch./Drug Res. 43 (1), Nr. 6 (1993)

[45] Leutner V
Schlaf und Schlafmittel. Zur Physiologie, Pharmakologie und Klinik des
Schlafes
Med. Welt Bd. 27/Heft 1 1976 pp 1-10

[46] Lindahl O, Lindwall L
Double Blind Study of a Valerian Preparation

[47] Meier B
Baldrian. Traditionelles Schlafmittel
Der Allgemeinarzt 14 (1992) 1102-12

In vitro study on the interaction of extracts and pure compounds from
Valeriana officinalis roots with GABA, benzodiazepine and barbiturate
receptors in rat brain
Fitoterapia Volume LXIV, No. 4, 1993

Valeriana officinalis: traditional use and recent evaluation of activity
Fitoterapia 66/2 (1995) 99-112

[50] Müller-Limmroth W, Ehrenstein W
Untersuchungen über die Wirkung von Seda-Kneipp® auf den Schlaf
schlafgestörter Menschen
Newall CA, Anderson LA, Phillipson JD
Herbal Medicines. A guide for Health-Care Professionals
The Pharmaceutical Press, London 1996

Orth-Wagner S, Ressin WJ, Friederich I
Phytosedativum gegen Schlafstörungen
Z. Phytother. 16 (1995) 147-56

Perucchi S, Hasler A
Drug Monitoring Study: Zeller-Schlafsirup ohne Alkohol
unpublished report, Zeller-AG

Rasmussen P
A role for phytotherapy in the treatment of benzodiazepine and opiate drug withdrawal (Part 1)
The European Journal of Herbal Medicine, Vol. 3 (1997) No. 1, pp. 11-21

Rodenbeck A, Simen S, Cohrs S, Jordan W, Kinkelbur J, Staedt J, Hajak G
Veränderte Schlafstadienstruktur als Hinweis auf die GABAerge Wirkung eines Baldrian-Hopfenpräparates bei Patienten mit psychophysiologischer Insomnie
Somnologie (1998) 2, 26-31

Rücker G, Tautges J, Sieck A, Wenzl H, Graf E
Untersuchungen zur Isolierung und pharmakodynamischen Aktivität des Sesquiterpens Valeranon aus Nardostachys DC
Arzneim. Forsch./Drug Res. 28 (I) 1 (1978) 7-1

Santos Maria S et al
An Aqueous Extract of Valerian Influences the Transport of GABA in Synaptosomes
Planta Med. 60 (1994) 278-279

Santos Maria S et al
The Amount of GABA Present in Aqueous Extracts of Valerian is Sufficient to Account for [³H] GABA Release in Synaptosomes
Planta Med. 60 (1994) 475-476

Schilcher H
Pflanzliche Psychopharmaka. Eine neue Klassifizierung nach Indikationsgruppen
DAZ, 135 (20) 1811-22 (1995)

Schmidt-Voigt J
Die Behandlung nervöser Schlafstörungen und innerer Unruhe mit einem rein pflanzlichen Sedativum
Therapiewoche 36 (1986) 663-7
[61] Schulz H, Jobert M
Die Darstellung sedierender/tranquillisierender Wirkungen von Phytopharmaka im quantifizierten EEG

[62] Schulz H, Stolz C, Müller J
The Effect of Valerian Extract on Sleep Polygraphy in Poor Sleepers: A Pilot Study
Pharmacopsychiat. 27 (1994) 147-151

[63] Stoll A, Seebeck E, Staufacher D
Neuere Untersuchungen über Baldrian
Schweizerische Apotheker-Zeitung Bd 95 1957 S. 115-120

[64] Thies PW, Funke S
Über die Wirkstoffe des Baldrians
Tetrahedon Letters No. 11, pp. 1155-1162, 1966, Pergamon Press Ltd., Printed in Britain

[65] USP
US Consumer Information: Valerian (Oral)
1998

[66] Vorbach EU, Görtelmeyer R, Brüning J
Therapie von Insomnien. Wirksamkeit und Verträglichkeit eines Baldrianpräparates
Psychopharmakotherapie 3 (1996) 109-15

[67] Willey LB, Mady SP, Cobaugh DJ, Wax PM
Valerian Overdose: A Case Report